International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 7.23.2020
COVID-19 Update: Staying Safe and Hopeful, Buoyed by Positive Early Results in Vaccine and Treatment Research
As the coronavirus pandemic persists in parts of the U.S. this week, results of two clinical trials of vaccinations were reported. “This was welcomed good news,” says IMF Chairman Dr. Brian G.M. Durie, who highlights measures to stay safe and keep a positive attitude during this challenging time. Animals that are thriving include humpback whales, he notes, which appreciate the new quiet in Alaska’s Glacier Bay.
Register for the Next IMF Patient & Family Webinar
The next IMF Patient & Family Webinar is scheduled for Saturday, August 15, at 1:00 p.m. PT / 4:00 p.m. ET. This FREE two-hour webinar features a panel discussion about the latest treatments for and management of myeloma led by IMF Chairman Dr. Brian G.M. Durie. Panelists include Dr. Joseph Mikhael of Translational Genomics Research Institute (TGen), Dr. Thomas Martin of the University of California San Francisco (UCSF) Health, and patient advocate Jack Aiello.
Calling All Researchers: Submit Your Grant Applications
The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2021 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline to receive the applications is Saturday, August 1, 2020. 
IMF Support Groups: We Are Here for You!
As the COVID-19 respiratory virus spreads, the International Myeloma Foundation (IMF) continues to be here for you. To contain the spread of the virus, we provide services to ensure your support group can meet virtually. The IMF has available secure GoToMeeting licenses for support group leaders and group members to use at no cost! If you are new to this technology or need any assistance to encourage your members to meet online, contact Robin Tuohy, IMF Vice President, Support Groups.
Dr. Hans Lee Explains an Analysis Examining Renal Impairment in the DREAMM-2 Study
The DREAMM-2 Trial is an open-label study of belantamab mafodotin. In this video, Dr. Hans Lee (MD Anderson Cancer Center — Houston) discusses a post-hoc analysis of the DREAMM-2 study that was conducted to examine renal impairment.
And This Too Shall Pass….
Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself sipping a tropical beverage next to a private pool, just minutes from the Hawaiian coastline. 
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

COVID-19 FAQ #18: Is Ninlaro® a safe treatment alternative for myeloma patients during the pandemic?
Watch Now
Clinical Trials

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Upcoming Events
Miracles for Myeloma
Virtual 5K Run/Walk/Bike

Watch a Replay
Post-ASCO / Post-EHA Webinar

Hatfield Hike
Appalachian Trail

Click here to see all events

We Thank Our Sponsors:

Amgen, Bristol-Myers Squibb, Genentech, GSK, Oncopeptides Inc., Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page